<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364511">
  <stage>Registered</stage>
  <submitdate>28/06/2013</submitdate>
  <approvaldate>1/07/2013</approvaldate>
  <actrnumber>ACTRN12613000717752</actrnumber>
  <trial_identification>
    <studytitle>The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes</studytitle>
    <scientifictitle>A randomised placebo controlled crossover trial to evaluate the effects of 5 weeks resveratrol supplementation on GLP-1 secretion, gastric emptying, and postprandial glycaemia in patients with type 2 diabetes mellitus</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>type 2 diabetes mellitus</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Each patient will undergo two 5 week treatment periods, one with resveratrol 500mg capsules twice daily and one with placebo, in double- blind, randomised fashion, separated by 5 weeks. They will attend the laboratory on the first and last day of each treatment period to consume a mashed potato meal labelled with 13C-octanoic acid. Compliance will be monitored by capsule counts at each study visit and by twice weekly telephone calls. </interventions>
    <comparator>Matching placebo capsules</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Plasma total GLP-1 concentrations</outcome>
      <timepoint>Concentrations measured at T = -5, 15, 30, 45, 60, 90, 120, 150, 180 and 240 min in relation to consumption of the test meal at T = 10 min</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Gastric half-emptying time as measured by 13C-octanoic breath test</outcome>
      <timepoint>Breath samples collected at T=5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 min and then every 15 min until T = 240 min</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood glucose concentrations</outcome>
      <timepoint>Concentrations measured at T = -5, 15, 30, 45, 60, 90, 120, 150, 180 and 240 min in relation to consumption of the test meal at T = 10 min</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- Patients with a diagnosis of type 2 diabetes by WHO criteria (plasma glucose 7 mmol/L or greater fasting, or 11.1 mmol/L or greater two hours after a glucose challenge) or with a history of HbA1c 6.5% or greater, managed by diet alone.
- Body mass index (BMI) 20 - 35 kg/m2
- Age 20  75 years
- Males and post-menopausal females (the latter based on history).
- HbA1c 7.9% or less
- Haemoglobin above the lower limit of the normal range (ie. &gt;130g/L in males and 120g/L in females) and ferritin above the lower limit of normal (ie. &gt;15 mcg/L in females and 30 mcg/L in males)
</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>- Use of any medication, within a period of 5 half-lives or less before the study, that may influence gastrointestinal motor function (eg: opiates, anticholinergics, levodopa, calcium-channel antagonists, beta blockers, clonidine, nitrates, tricyclic antidepressants, selective serotonin re-uptake inhibitors, phosphodiesterase type 5 inhibitors, sumatriptan, metoclopramide, domperidone, cisapride, tegaserod, or erythromycin).
- Intake of &gt; 20 g alcohol on a daily basis, or cigarette smoking
- Inability to tolerate the standardized meals (eg. strict vegetarians, subjects with food allergies such as egg allergy, and those on a gluten-free diet).
- History of gastrointestinal disease, including chronic abdominal symptoms or a diagnosis of gastroparesis
- Unstable cardiac disease, specifically those with cardiac symptoms such as angina or dyspnea, not adequately controlled by medications.
- Impaired renal function (eGFR of &lt;60 mL/min/1.73 m2).
- Impaired liver function (liver enzymes twice the upper limit of normal or greater).
- Donation of blood within the previous 3 months
- Participation in any other research studies within the previous 3 months
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>numbered containers</concealment>
    <sequence>computer-generated random number table</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>15/07/2013</anticipatedstartdate>
    <actualstartdate>30/09/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>15</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Adelaide Hospital</primarysponsorname>
    <primarysponsoraddress>North Terrace Adelaide South Australia 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Gum Bequest, Endocrine and Metabolic Unit, Royal Adelaide Hospital</fundingname>
      <fundingaddress>Endocrine and Metabolic Unit, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia 5000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Resveratrol, which is a nutritional supplement derived from certain plant foods including red grapes, has the potential to improve blood sugar levels in patients with type 2 diabetes by uncertain mechanisms. In this study, we aim to identify the effects of resveratrol on the rate of gastric emptying, blood sugar levels and blood levels of hormones produced by the intestines</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>Level 3, Hanson Institute Royal Adelaide Hospital, North Terrace, Adelaide SA 5000</ethicaddress>
      <ethicapprovaldate>30/05/2013</ethicapprovaldate>
      <hrec>130229</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Chris Rayner</name>
      <address>Discipline of Medicine Royal Adelaide Hospital North Terrace Adelaide SA 5000</address>
      <phone>+61 8 82222916</phone>
      <fax>+61 8 82233870</fax>
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Chris Rayner</name>
      <address>Discipline of Medicine Royal Adelaide Hospital North Terrace Adelaide SA 5000</address>
      <phone>+61 8 82222916</phone>
      <fax>+61 8 82233870</fax>
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Chris Rayner</name>
      <address>Discipline of Medicine Royal Adelaide Hospital North Terrace Adelaide SA 5000</address>
      <phone>+61 8 82222916</phone>
      <fax>+61 8 82233870</fax>
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Chris Rayner</name>
      <address>Discipline of Medicine Royal Adelaide Hospital North Terrace Adelaide SA 5000</address>
      <phone>+61 8 82222916</phone>
      <fax>+61 8 82233870</fax>
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>